AMRI Announces Changes in India Operations

AMRI (NASDAQ: AMRI) announced today the following changes to its India operations and leadership team, supporting the establishment of an integrated offering of chemical development and manufacturing services as part of an effort to increase efficiencies of AMRI’s global operations and to reduce costs.

Promoted to the leadership role for all AMRI operations in India is Rajesh Shenoy, Ph.D. as managing director, India operations. Previously director for the company’s site in Hyderabad, India, Dr. Shenoy’s role has expanded to include large scale commercial manufacturing operations in Aurangabad, India. He assumed leadership for Hyderabad operations in 2005 as part of the AMRI team that established one of the company’s first sites outside of the United States, and the first in India. Dr. Shenoy will report to Steven R. Hagen, Ph.D., AMRI vice president of pharmaceutical development and manufacturing.

Also promoted is Mr. Sivakumar Sivasubramanian to director, general operations to assume oversight for all general plant operations and engineering services for AMRI in India. Mr. Sivasubramanian joined AMRI in Hyderabad in 2005 as general manager, operations, and was also instrumental in the establishment of the company’s first facility in India.

Sridhar Vaddeboina, Ph.D., most recently manager, analytical quality services for India operations, has been promoted to director of analytical services, India Operations. In this expanded role, Dr. Vaddeboina will lead all analytical and quality functions in India.

"We are pleased to announce the promotions of Drs. Shenoy and Vaddeboina and Mr. Sivasubramanian into these expanded leadership roles,” said AMRI Chairman, CEO and President Thomas E. D’Ambra, Ph.D. "Besides benefiting from their ability to achieve positive results as demonstrated by their efforts in establishing and growing our Hyderabad site, we believe that there will be significant synergies and collaborative benefits gained by combining leadership of the entire AMRI India footprint under one helm.”

Dr. D’Ambra continued, "We are proud of the efforts to date of these three employees highlighted today and congratulate them for their accomplishments and wish them the best in their expanded roles. AMRI remains committed to seeking and implementing initiatives that will result in increased value to our customers and stakeholders. We believe these most recent changes provide significant strategic and marketing advantages, including increased collaboration and productivity, enhanced technology transfer and shortened production time, and cost savings.”

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Forward-Looking Statements

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, but are not limited to, statements by AMRI’s Chairman, CEO and President and statements concerning the performance of the company’s global chemistry platform. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission on March 13, 2009 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5986271&lang=en